Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling the Peaks
(Stocks hitting 52-week highs on May 23)
- ABIOMED, Inc. (NASDAQ: ABMD)
- ArQule, Inc. (NASDAQ: ARQL)
- Crispr Therapeutics AG (NASDAQ: CRSP)
- Evolus Inc (NASDAQ: EOLS)
- Immunomedics, Inc. (NASDAQ: IMMU)
- Merit Medical Systems, Inc. (NASDAQ: MMSI)
- Mersana Therapeutics Inc (NASDAQ: MRSN)
- Mirati Therapeutics Inc (NASDAQ: MRTX)
- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)
- Novus Therapeutics Inc (NASDAQ: NVUS)
- Retrophin Inc (NASDAQ: RTRX)
- SurModics, Inc. (NASDAQ: SRDX)
- Tecogen Inc (NASDAQ: TGEN)
- Xencor Inc (NASDAQ: XNCR)
Down In The Dumps
(Stocks hitting 52-week lows on May 23)
- Ardelyx Inc (NASDAQ: ARDX) (following its capital raising program)
- Cellectar Biosciences Inc (NASDAQ: CLRB)
- Edge Therapeutics Inc (NASDAQ: EDGE)
- PAVmed Inc (NASDAQ: PAVM)
- Soligenix, Inc. Common Stock (NASDAQ: SNGX)
- Unity Biotechnology Inc (NASDAQ: UBX)
Stocks In Focus Novartis Unit Gets EC Approval For Autoimmune Disease Therapy
Novartis AG (ADR) (NYSE: NVS)'s Sandoz unit announced that the European Commission has approved its Zessly for use in Europe. Zessly is approved for several indications such as rheumatoid arthritis, adult Crohn's disease, pediatric ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis.
Melinta Prices Common Stock Offering
Melinta Therapeutics, Inc. (NASDAQ: MLNT) said it has priced its 22 million common stock offering at $5 per share.
Melinta's shares fell 2.82 percent to $6.05 after hours.
Cytori Begins to Trade On Split-adjusted Basis
Following the reverse split, the number of outstanding shares was reduced from 61.6 million to 6.2 million.
Eiger Announces Common Stock Offering
Eiger Biopharmaceuticals Inc (NASDAQ: EIGR) announced an underwritten common stock offering, with all shares to be sold by the company.
The company said it intends to use the proceeds to fund the Phase 3 clinical trial of lonafarnib in Hepatitis Delta Virus infection, regulatory development of lonafarnib related to the treatment of Hutchison-Gilford Progeria Syndrome, and for working capital and other general corporate purposes.
The stock fell 4.30 percent to $13.35 after hours.
Ultragenyx Releases Results of X-linked Hypophosphatemia Drug Trial
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and its Japanese partner Kyowa Hakko Kirin announced a Phase 2 trial that evaluated their crysvita for treating X-linked hypophosphatemia, or XLH, in children aged 5-12 years showed improvement in rickets severity, growth, pain and physical function, and increased serum phosphorus and renal phosphate reabsorption.
The results were published in the New England Journal of Medicine. Previously, top-line results from the study were published in April 2017.
Apellis, Marinus Up On Sell-Side Initiations
Cantor Fitzgerald initiated coverage of Apellis with an Outperform rating and a $52 price target. Marinus was started with an Outperform rating and a $15 price target, with the optimism premised on the impending release of mid-stage trial data for its post-partum depression treatment candidate.
See more from Benzinga
- Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing
- Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict
- Dova Receives FDA Nod For Bleeding Disorder Treatment; Rival Drug Awaits Clearance
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.